Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Exhibit 99.1 contains the actual disclosed material; investor-relevant content resides there, not in the boilerplate item text.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 contains the actual disclosed material; investor-relevant content resides there, not in the boilerplate item text
- Reg FD filing signals Rhythm Pharmaceuticals shared material non-public information publicly, likely a clinical update, partnership, or business development event worth monitoring
Item 8.01 · Other Events
- Setmelanotide hit primary endpoint in 142-patient TRANSCEND trial: -16.4% BMI reduction vs +2.4% for placebo at 52 weeks (p<0.0001)
- Placebo-adjusted BMI reduction of -18.8%, a clinically meaningful delta supporting drug efficacy in hypothalamic obesity
- Hunger score improvement statistically significant in patients 12+: 2.5-point reduction vs 1.3-point for placebo (p=0.0015)
- Expanded dataset includes Japanese cohort (12 patients) + 10 supplemental patients beyond primary 120-patient pivotal cohort: broadens global regulatory optionality
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.